JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

This is an open-label, multicenter Phase I study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of JH021 injection in patients with advanced solid tumors. JH021 is a bispecific monoclonal antibody targeting EGFR and cMET. The study will assess JH021 in patients with advanced solid tumors for whom standard therapy is unavailable, intolerable, or no longer effective, and will provide data to support further clinical development.

NCT Number	NCT07582822
Lead Sponsor	Biotech Pharmaceutical Co., Ltd.
Conditions	Advanced Solid Tumor
Enrollment	60 participants
Start Date	2026-05-30
Primary Completion	2028-05-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-13